NCT03478462View on ClinicalTrials.gov

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

December 25, 2025

Study Completion Date

December 31, 2026

Conditions
Pediatric Solid TumorPediatric LymphomaPediatric Brain TumorDIPGNeuroblastomaEwing SarcomaRhabdomyosarcomaOsteosarcoma
Interventions
DRUG

CLR 131

IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose

Trial Locations (8)

2145

Children's Hospital at Westmead, Westmead

10065

Memorial Sloan Kettering Cancer Center, New York

27708

Duke University, Chapel Hill

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

53792

University of Wisconsin Hospital and Clinics, Madison

77030

Texas Children's Hospital, Houston

94304

Lucile Packard Children's Hospital, Palo Alto

M5G1X8

Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
lead

Cellectar Biosciences, Inc.

INDUSTRY